Female HypogonadismTHSNCT07315932
Perception of Hormonal Replacement Therapy Among Patients Aged 11 to 17 Years
An observational study of Female Hypogonadism, run by University Hospital, Strasbourg, France at 1 site in France.
Trial summary
To establish a current knowledge and perception of patients and their parents regarding HRT in order to assess the needs that can promote understanding and adherence to treatment by implementing therapeutic education workshops Read more about this study
- Who is it for?
- Ages 11 to 18 years, women only
- Conditions the study is for
- Female Hypogonadism
- How many people
- 20 participants
- Where
- 1 siteFrance
- Study dates
- 23 Mar 2025to Feb 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 11 to 18 years
- Women only
- Child, Adult
Study population: Female patients aged 11 to 18 years treated at the University Hospital of Strasbourg for central or peripheral hypogonadism with the initiation of hormone replacement therapy
Who may be able to join
- Female patients aged 11 to 18 years
- Treated at the University Hospital of Strasbourg for central or peripheral hypogonadism with the initiation of hormone replacement therapy
Who cannot join
- Inability to provide the subject with clear information (difficulties understanding the subject, language barrier, illiteracy, etc.)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Service de Gynécologie et obstétrique - CHU de Strasbourg - France
Strasbourg, 67091
Mathilda KRETZ, MD, 33 3 88 11 67 68, mathilda.kretz@chru-strasbourg.fr
Mathilda KRETZ, MD
About this study
Official title: Current Knowledge and Perceptions of Hormone Replacement Therapy Among Patients Aged 11 to 18 Years, and Their Parents, Treated for Hypogonadism at the Strasbourg University Hospital
To establish a current knowledge and perception of patients and their parents regarding HRT in order to assess the needs that can promote understanding and adherence to treatment by implementing therapeutic education workshops
- Conditions
- Female Hypogonadism
- Keywords
- Female Hypogonadism, Central hypogonadism, Peripheral hypogonadism, hormone replacement therapy
- Medical subject headings
- Hypogonadism
What is being measured
The primary outcome is the main question the study is designed to answer.
Assessment of patients' knowledge about the composition of hormonal treatment for female hypogonadism
The aim is to assess the knowledge of patients aged 11 to 18 about the composition of hormone treatment for female hypogonadism using a questionnaire.
Measured: Up to 7 months
Assessment of patients' knowledge regarding the effects of hormonal treatment for female hypogonadism
The aim is to assess the knowledge of patients aged 11 to 18 years about the effects of hormone treatment for female hypogonadism using a questionnaire.
Measured: Up to 7 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jan 2026
- Study start23 Mar 2025
- Primary completionFeb 2026 (estimated)
- Study completionFeb 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Female HypogonadismStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07315932
- Sponsor's protocol ID
- 9620
- Acronym
- THS
- Status last verified
- Dec 2025
- First submitted
- 18 Dec 2025
- Last updated
- 5 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Current Knowledge and Perceptions of Hormone Replacement Therapy Among Patients Aged 11 to 18 Years, and Their Parents, Treated for Hypogonadism at the Strasbourg University Hospital
- ClinicalTrials.gov ID
- NCT07315932
- Acronym / sponsor ID
- THS / 9620
- Conditions
- Female Hypogonadism
- Keywords
- Female Hypogonadism, Central hypogonadism, Peripheral hypogonadism, hormone replacement therapy
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Study start
- 23 Mar 2025 (actual)
- Primary completion
- Feb 2026 (estimated)
- Study completion
- Feb 2026 (estimated)
- First posted
- 5 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To establish a current knowledge and perception of patients and their parents regarding HRT in order to assess the needs that can promote understanding and adherence to treatment by implementing therapeutic education workshops
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 11 to 18 years
- Sex
- Female only
- Age groups
- Child, Adult
- Study population
- Female patients aged 11 to 18 years treated at the University Hospital of Strasbourg for central or peripheral hypogonadism with the initiation of hormone replacement therapy
Key inclusion criteria (2 listed)
- Female patients aged 11 to 18 years
- Treated at the University Hospital of Strasbourg for central or peripheral hypogonadism with the initiation of hormone replacement therapy
Key exclusion criteria (1 listed)
- Inability to provide the subject with clear information (difficulties understanding the subject, language barrier, illiteracy, etc.)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Assessment of patients' knowledge about the composition of hormonal treatment for female hypogonadism
Time frame: Up to 7 months
The aim is to assess the knowledge of patients aged 11 to 18 about the composition of hormone treatment for female hypogonadism using a questionnaire.
Assessment of patients' knowledge regarding the effects of hormonal treatment for female hypogonadism
Time frame: Up to 7 months
The aim is to assess the knowledge of patients aged 11 to 18 years about the effects of hormone treatment for female hypogonadism using a questionnaire.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jan 2026.
Related trials for Female Hypogonadism
RecruitingObservational study
Inherited Reproductive Disorders
Genetic Disorder, Infertility
Active, not recruitingPhase 2
Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity
Hypothalamic Obesity, Hypothalamic Tumor
Active, not recruitingPhase 1/2
A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
Hypothalamic Obesity, Prader-Willi Syndrome
Not yet recruitingPhase 3
SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years
Craniopharyngioma, Child
Active, not recruiting
Effects of Estrogen Therapy on Lipid Metabolism and Insulin Sensitivity in Hypogonadal Women
Female Hypogonadism
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Female Hypogonadism, run by University Hospital, Strasbourg, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mathilda KRETZ, MD (33 3 88 11 67 68, mathilda.kretz@chru-strasbourg.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assessment of patients' knowledge about the composition of hormonal treatment for female hypogonadism (time frame: Up to 7 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jan 2026.